Skip to main content

US FDA accepts for review Otsuka and Lundbeck's sNDA filing for labeling update of Rexulti® (brexpiprazole)

 

Clinical courses

H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental.

New Drug Application (sNDA) for the proposed labeling update of Rexulti (brexpiprazole) for the maintenance treatment of adults with schizophrenia. Under the Prescription Drug User Fee Act (PDUFA), the PDUFA date is 23 September 2016.

The sNDA is supported by results from a 52-week randomized withdrawal trial in adults with schizophrenia aged 18 to 65 years. In the trial, patients were stabilized on Rexulti and were then randomized to continued therapy with Rexulti (n=96) or placebo (n=104).

The primary endpoint of the study was time from randomization to relapse. At a pre-specified interim analysis, the study demonstrated a statistically significantly longer time to relapse in patients randomized to the Rexulti group (1 mg/day to 4 mg/day) compared to placebo-treated patients and the trial was terminated early because maintenance of efficacy had been demonstrated (p < 0.0001, final analysis). During the randomized maintenance phase, adverse reactions were similar to those reported in the short-term schizophrenia trials.

<< Pharma News

Subscribe to PharmaTutor News Alerts by Email >>